For the interim period of the fiscal year ending March 2027, consolidated net sales were 31,353 million yen, up 7.1% year-over-year; operating income was 5,468 million yen, down 17.4% year-over-year; and interim net income attributable to owners of parent was 4,430 million yen, down 7.2% year-over-year. Year-end dividend is 56 yen, commemorative dividend 0 yen, with a full-year dividend forecast of 81 yen. Newly consolidated JLL Med USA Inc. was added to the scope of consolidation. Selling, general and administrative expenses increased due to higher investment in new product development, which pressured profits. New areas such as cerebrovascular and gastrointestinal segments performed well. Full-year forecasts are unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7575","jir_company_name":"Japan Lifeline Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/7575-20261030-01.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, consolidated net sales were 31,353 million yen, up 7.1% year-over-year; operating income was 5,468 million yen, down 17.4% year-over-year; and interim net income attributable to owners of parent was 4,430 million yen, down 7.2% year-over-year. Year-end dividend is 56 yen, commemorative dividend 0 yen, with a full-year dividend forecast of 81 yen. Newly consolidated JLL Med USA Inc. was added to the scope of consolidation. Selling, general and administrative expenses increased due to higher investment in new product development, which pressured profits. New areas such as cerebrovascular and gastrointestinal segments performed well. Full-year forecasts are unchanged.","jir_summary":"### Overview of Business Results\nWhile demand for medical devices is expected to expand, particularly in the domestic market due to an aging population, selling, general and administrative expenses increased because of higher raw material and labor costs and strengthened investment in new product development. Although net sales expanded steadily year-over-year, operating income declined due to the impact of new investments. Strong performance was driven by growth in EP\/ablation and in new areas such as cerebrovascular and gastrointestinal fields. Conversely, the rhythm device segment experienced a decline in sales. The company will continue to strengthen global expansion and maintain research and development investment to drive future growth.\n\n### Financial Position, Cash Flows and Outlook\nTotal assets at the end of the interim period were 80,005 million yen, and net assets were 66,414 million yen. Cash and deposits decreased to 11,711 million yen. Cash outflows occurred due to dividend payments. Given certain acquisition-related expenditures and higher personnel costs, the full-year forecast for the fiscal year ending March 2027 remains unchanged. From the third quarter onward, expenditures will be managed and are expected to progress within the full-year plan. The consolidation effects of the new subsidiary are also taken into account.","jir_financial_highlights":"Net Sales: 31,353 (Year-over-Year +7.1%)\nOperating Income: 5,468 (Year-over-Year -17.4%)\nOrdinary Income: 6,040 (Year-over-Year -8.8%)\nNet Income Attributable to Owners of Parent (Interim): 4,430 (Year-over-Year -7.2%)\nNet Income per Share (Interim): 63.15 (Unknown)\nEquity Ratio: 82.9 (Quarter-on-Quarter +0.8pt)","jir_category":"","jir_hashtags":"#JapanLifeline, #InterimFinancialResults, #MedicalDevices","jir_key_figures":"Net Sales: 31,353 million yen (Year-over-Year +7.1%)\nOperating Income: 5,468 million yen (Year-over-Year -17.4%)\nNet Income Attributable to Owners of Parent (Interim): 4,430 million yen (Year-over-Year -7.2%)","jir_meta_title":"Japan Lifeline Co., Ltd. Q2 FY2027 Financial Summary | Net Sales 31,353 million yen, Operating Profit Decline","jir_meta_description":"Summary of Japan Lifeline Co., Ltd.'s Q2 FY2027 consolidated results: net sales increased while profits declined due to new investments and rising raw material costs. Analysis includes the impact of a newly consolidated subsidiary and outlook.","jir_og_title":"Japan Lifeline Co., Ltd. FY2027 Q2 Results: Sales Growth but Profit Pressure","jir_og_description":"Japan Lifeline Co., Ltd.'s Q2 FY2027 consolidated results show higher sales but decreased profits. Includes discussion of the newly consolidated subsidiary and future growth strategy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9484,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138800","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n